Osteoarthritis Market Report 2026

The osteoarthritis market size has grown strongly in recent years. It will grow from $7.49 billion in 2025 to $8.16 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to rising prevalence of osteoarthritis globally, limited availability of advanced joint therapies in early periods, increasing aging population with joint degeneration, early adoption of conventional medications and surgeries, growing awareness of joint health and pain management.

The osteoarthritis market size is expected to see strong growth in the next few years. It will grow to $11.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising adoption of minimally invasive and robotic-assisted surgeries, increasing use of biologics and dmoads, expanding healthcare infrastructure for joint care, growing adoption of digital diagnostics and ai-based monitoring, increasing patient awareness of lifestyle and weight management programs. Major trends in the forecast period include rising adoption of minimally invasive joint replacement surgeries, increasing use of biologic therapies and hyaluronic acid injections, growing integration of digital imaging and ai-based diagnostics, rising focus on personalized osteoarthritis management plans, increasing investment in physical therapy and rehabilitation programs.

The rise in obesity-related disorders is expected to drive growth in the osteoarthritis market in the coming years. Obesity-related problems encompass a range of health issues caused by excessive body fat, often resulting from consuming more calories than are burned through physical activity, eating large amounts of processed or fast food, and excessive alcohol consumption. Obesity contributes to osteoarthritis by placing additional strain on joints, triggering inflammation, and altering hormone levels, all of which increase joint stress. For instance, in September 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that the number of states with adult obesity prevalence of 35% or higher increased from 22 states in 2022 to 23 states in 2023. Therefore, obesity-related disorders are fueling the growth of the osteoarthritis market.

Companies in the osteoarthritis market are increasingly pursuing strategic partnerships to enhance technology integration and expand their market reach. Strategic partnerships involve collaborative relationships where organizations pool resources, expertise, and efforts to achieve shared objectives. For example, in July 2024, LG Chem, a South Korea-based pharmaceutical company, entered the Chinese market through a partnership with Yifan Pharmaceutical Co., Ltd., a China-based pharmaceutical research and production company. This collaboration launched Synovian injection for osteoarthritis, offering similar therapeutic effects to traditional multi-injection formulations but with a single administration. Synovian’s high molecular weight (10 million Dalton) hyaluronic acid enhances viscoelasticity and joint function, and clinical phase 3 trials demonstrated significant knee pain reduction, positioning it as an effective and convenient treatment option for osteoarthritis patients.

In November 2023, Smith & Nephew, a UK-based medical technology company specializing in orthopaedics, sports medicine, arthroscopic technologies, and wound care, acquired CartiHeal for US$180 million upfront. This acquisition expands Smith & Nephew’s osteoarthritis and joint-repair portfolio by integrating biologic cartilage-regeneration technology, strengthening its long-term leadership in sports medicine. CartiHeal, an Israel-based company, develops the Agili-C scaffold, a porous, biocompatible implant designed for one-step repair of cartilage and subchondral bone in knees with osteochondral lesions, including cases of mild to moderate osteoarthritis.

Major companies operating in the osteoarthritis market are Pfizer Inc., Johnson & Johnson, Merck Sharp & Dohme Corp., Abbvie Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories Incorporation, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Zimmer Biomet Holdings Inc., Eisai Co. Ltd., Horizon Therapeutics plc, Apotex Inc., Mallinckrodt Pharmaceuticals, Pacira BioSciences Inc., Bioventus Inc., Endo Pharmaceuticals Inc., Assertio Therapeutics Inc., Anika Therapeutics Inc., Abiogen Pharma Spa, Kolon TissueGene Inc., Ampio Pharmaceuticals Inc.

North America was the largest region in the osteoarthritis market in 2025. The regions covered in the osteoarthritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteoarthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the osteoarthritis market by raising costs of imported surgical instruments, biologic therapies, imaging equipment, and rehabilitation devices. Hospitals, medical institutes, and clinics in north america, europe, and asia-pacific are most affected due to reliance on imported medical technologies. Tariffs have increased treatment costs and delayed equipment procurement. However, they have also encouraged local manufacturing, investment in domestic medical devices, and development of regional supply chain resilience.

The osteoarthritis market research report is one of a series of new reports that provides osteoarthritis market statistics, including osteoarthritis industry global market size, regional shares, competitors with a osteoarthritis market share, detailed osteoarthritis market segments, market trends and opportunities, and any further data you may need to thrive in the osteoarthritis industry. This osteoarthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Osteoarthritis is a type of arthritis that affects the joints, commonly the hands, knees, hips, neck, and lower back. It occurs when the cartilage that cushions the ends of bones gradually wears away. Treatment for osteoarthritis focuses on reducing pain, improving joint function, and slowing disease progression.

The main treatments for osteoarthritis include medication, surgery, and therapy. Medications are used to manage or relieve symptoms and may include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids. Diagnosis typically involves imaging and joint fluid analysis. Medications can be administered orally, topically, or via parenteral routes for conditions such as knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, and hand osteoarthritis. End users include hospitals and medical institutes.

The osteoarthritis market consists of revenues earned by entities by providing services such as physical therapy, occupational therapy, weight management, exercise and physical activity, patient education, self-management programs and joint protection techniques. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoarthritis market also includes sales of viscosupplementation agents, analgesics, corticosteroids and assistive devices such as braces, canes, or shoe inserts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.